IRIDEX Corporation — Form 10-Q Summary
Reporting period: Quarter ended June 28, 2014; comparisons are with the quarter ended June 29, 2013. Six-month figures compare the periods ended on those dates. Financial statement amounts are in thousands of dollars, except per-share data.
Business context
IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices, consumables, and service and support. It operates as one ophthalmology segment, selling directly and through independent sales representatives in the United States and distributors internationally. Management attributed system-sales growth to adoption of MicroPulse laser therapy and increased TxCell scanning delivery-system sales.
Financial performance
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $10.589 million | $9.210 million | $20.918 million | $18.149 million |
| Gross profit | $5.300 million | $4.482 million | $10.355 million | $8.713 million |
| Gross margin | 50.0% | 48.7% | 49.5% | 48.0% |
| Operating income | $0.400 million | $0.515 million | $0.997 million | $1.412 million |
| Net income | $0.297 million | $0.415 million | $0.784 million | $1.289 million |
| Diluted EPS | $0.03 | $0.04 | $0.07 | $0.13 |
- Q2 revenue increased 15.0%; six-month revenue increased 15.3%. Q2 domestic system sales rose 83.7%, international system sales rose 6.4%, and recurring revenue was essentially flat. For the first half, domestic and international system sales increased 52.4% and 19.2%, respectively, while recurring revenue rose 3.0%.
- Gross margin improved in both comparison periods, with management citing production overhead efficiencies and direct-margin gains, partly offset by manufacturing variances. Higher system sales also reduced the proportion of higher-margin recurring revenue.
- Despite higher revenue and gross margin, operating income and net income declined. Operating expenses rose, including research and development, sales and marketing, and general and administrative costs. First-half 2013 operating results also included a $473,000 insurance-carrier demutualization gain that did not recur.
- Research and development spending increased 47.7% in Q2 and 33.0% for the first half, primarily reflecting product-platform cost-reduction and development programs, plus staffing. Management said it expected these program expenditures to continue until completion. Sales and marketing spending is also expected to continue increasing to support sales.
Cash, liquidity and obligations
- Cash and cash equivalents were $12.862 million at June 28, 2014, down from $13.444 million at December 28, 2013. Working capital was $24.3 million, compared with $24.6 million at year-end.
- For the first half, operating activities provided $1.423 million; investing activities used $608,000, including capital expenditures and earn-out payments; financing activities used $1.397 million. The company repurchased $2.246 million of shares, partly offset by $849,000 of stock-option exercise proceeds.
- The filing reports no fixed- or variable-rate debt outstanding. Management stated that cash and expected operating cash flows should be sufficient for the next 12 months.
- Contractual obligations totaled $8.980 million: $753,000 of operating leases and $8.227 million of purchase commitments, primarily for components and ophthalmic instrumentation. Most are due within one year. The company reported no material off-balance-sheet arrangements.
Outlook, risks and unusual items
- Management described the outlook for system sales as positive, citing wider global adoption of MicroPulse therapy. This is not quantified earnings or revenue guidance; the filing does not provide specific numerical guidance.
- Bausch & Lomb discontinued the product incorporating IRIDEX’s OEM laser module; related OEM sales ceased. Management also noted first-half recurring-revenue growth from its independent sales force and increased sales of licensed GreenTip products by Alcon.
- Key risks include quarterly and seasonal variability, competition and alternative treatments, reimbursement uncertainty, reliance on international distributors and limited-source suppliers, product-development and regulatory risks, and potential product-quality or liability issues. The filing notes that European third-quarter sales are generally lower during summer holidays.
- International sales represented 43.5% of Q2 revenue. Sales are denominated in U.S. dollars, but a stronger dollar could make products less competitive abroad; the company did not hedge currency exposure.
- The earn-out liability was valued at $551,000 at quarter-end using Level 3 assumptions; its fair-value remeasurement contributed to other expense. Management reported no impairment of goodwill in its second-quarter annual test. Deferred tax assets of approximately $10 million were fully offset by a valuation allowance at December 28, 2013.
- Management concluded that disclosure controls were effective as of June 28, 2014 and reported no material change in internal control over financial reporting. It stated that ordinary-course legal matters were not expected to have a material adverse effect.
Important facts for investors to verify
- Whether MicroPulse and TxCell adoption continues to drive system sales, and whether recurring revenue grows alongside those sales.
- Whether increased operating expenses and ongoing development and sales investments translate into sustained operating-profit growth.
- Gross-margin trends, including manufacturing variances, product mix, and production efficiency.
- Cash generation relative to the $8.227 million of purchase commitments, share repurchases, and continuing operating needs.
- Progress with Alcon and other distribution channels, and the longer-term effect of discontinued Bausch & Lomb OEM sales.
- Changes in earn-out valuation, tax-asset valuation allowance, regulatory compliance, and supplier availability.